Monthly Archives:

Review of Survival Data From STAMPEDE Study

Chicago—The randomized, controlled STAMPEDE trial was presented during a session at the ASCO 2015 Annual Meeting by Nicholas David James and colleagues [J Clin Oncol. 2015;33; abstract 5001]. The study recruited men with high-risk locally advanced or metastatic prostate cancer (PC) who were starting long-term hormone therapy for the first time. The study initially assessed adding a variety of treatment ... Read More »

Prognosis Model Identifies Four Risk Factors Associated with Overall Survival

Chicago—Researchers have identified four readily available clinical and laboratory factors to generate a prognosis index model (PIM) for overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC). That was one of the findings of modeling conducted by researchers utilizing the final analysis dataset from COU-AA-302. Charles J. Ryan, MD, and colleagues reported their findings during a poster session ... Read More »

Abiraterone Acetate plus Enzalutamide in Modulation of Androgen Signaling

Chicago—Previous studies have observed a high degree of heterogeneity in cytoreduction in localized high-risk prostate cancer (LHRPC) after treatment with abiraterone acetate (AA) plus enzalutamide (AA + E) and leuprolide acetate (LHRHa) and AA plus LHRHa. According to Eleni Efstathiou, MD, PhD, and colleagues, a rationale exists for the AA + E combination therapy and promising efficacy has been reported ... Read More »

Results of Early Access Program for Overall Survival in Metastatic Castration-Resistant Prostate Cancer

Chicago—The results of an early access program (EAP) of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving radium-223 dichloride (Ra-223) were presented during a poster session at the ASCO 2015 Annual Meeting by Fred Saad and colleagues [J Clin Oncol. 2015;33; abstract 5034]. The poster was titled Radium-223 in an international early access program (EAP): Effects of concomitant medication on ... Read More »

Prostate Cancer Screening Rates in Privately Insured US Patients

Chicago—The US Preventive Services Task force recommends against prostate-specific antigen (PSA)-based screening for prostate cancer, giving the screening a grade D in a 2012 review. In addition, little is known about the degree to which prostate cancer screening has changed with recent clinical research data. A study was discussed during a poster presentation at the ASCO 2015 Annual Meeting by ... Read More »

RECIST Scores and Overall Survival in Prostate Cancer

Chicago—A recent study examined the association of changes in measurable disease via the Response Evaluation Criteria in Solid Tumors (RECIST) with overall survival (OS). The results were discussed during a poster presentation at the ASCO 2015 Annual Meeting by Gregory Russell Pond and colleagues that examined the national trends of prostate-specific antigen (PSA) screening to investigate which patient characteristics were ... Read More »

Radium-223 Dichloride Well-Tolerated in Pretreated Patients

New Orleans—Radium-223 dichloride (Ra-223) was well-tolerated with longer survival than seen previously in the phase 3 ALSYMPCA trial in a population of heavily pretreated patients in an expanded-access program. That was the primary finding of an analysis conducted recently by Neal Shore, MD, and colleagues. The researchers reported results of their analysis in a presentation at the AUA 2015 Annual ... Read More »

Perirectal Hydrogel Spacer Associated with Favorable Radiotherapy Outcomes

New Orleans—During prostate radiotherapy, prostate-rectum proximity can result in rectal irradiation, which limits the use of dose escalation and hypofractionation protocols. Though absorbable perirectal spacers are an option for the reduction of rectal irradiation, none have been studied in randomized, controlled trials. A study presented by Christopher Pieczonka, MD, during a session at the AUA 2015 Annual Meeting, was the ... Read More »

AA plus Prednisone 5 Mg Effective in Lowering PSA in Men with nmCRPC

New Orleans—In patients with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC), treatment with abiraterone acetate (AA) plus 5 mg of prednisone is very effective in lowering prostate-specific antigen (PSA). That was the primary finding of a phase 2, multicenter study conducted by Charles J. Ryan, MD, and colleagues. The researchers presented study results during a session at the AUA 2015 Annual ... Read More »

PHI Is Effective in Identification of Risk in Prostate Cancer Patients

New Orleans—There are two new serum markers associated with the risk and aggressiveness of prostate cancer: the Beckman Coulter Prostate Health Index (PHI) and [2]proPSA (p2PSA). E. David Crawford, MD, and colleagues recently conducted a study designed to determine whether PHI can be used for risk stratification of prostate cancer. The study’s results were reported during a presentation at the ... Read More »